CASTLE BIOSCIENCES INC

NASDAQ: CSTL (Castle Biosciences, Inc.)

Kemas kini terakhir: 17 Apr, 10:49AM

21.47

0.21 (0.99%)

Penutupan Terdahulu 21.26
Buka 21.14
Jumlah Dagangan 155,750
Purata Dagangan (3B) 406,577
Modal Pasaran 619,299,968
Harga / Pendapatan (P/E TTM) 34.63
Harga / Jualan (P/S) 1.77
Harga / Buku (P/B) 1.26
Julat 52 Minggu
16.97 (-20%) — 35.84 (66%)
Tarikh Pendapatan 5 May 2025
Margin Keuntungan 5.49%
Margin Operasi (TTM) 4.69%
EPS Cair (TTM) 0.620
Pertumbuhan Hasil Suku Tahunan (YOY) 30.50%
Jumlah Hutang/Ekuiti (D/E MRQ) 5.80%
Nisbah Semasa (MRQ) 7.29
Aliran Tunai Operasi (OCF TTM) 64.87 M
Aliran Tunai Bebas Leveraj (LFCF TTM) 29.45 M
Pulangan Atas Aset (ROA TTM) 1.10%
Pulangan Atas Ekuiti (ROE TTM) 4.31%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Diagnostics & Research (US) Menurun Menurun
Diagnostics & Research (Global) Menurun Menurun
Stok Castle Biosciences, Inc. Menurun Menaik

AISkor Stockmoo

-0.6
Konsensus Penganalisis 3.0
Aktiviti Orang Dalam NA
Volatiliti Harga -2.0
Purata Bergerak Teknikal -1.0
Osilator Teknikal -2.5
Purata -0.63

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
CSTL 619 M - 34.63 1.26
SHC 3 B - 74.56 7.93
TWST 2 B - - 3.85
NEOG 1 B - - 0.510
CDNA 834 M - 13.39 2.49
BIAF 12 M - - 4.96

Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.

Sektor Healthcare
Industri Diagnostics & Research
Gaya Pelaburan Small Core
% Dimiliki oleh Orang Dalam 3.35%
% Dimiliki oleh Institusi 93.97%
100.90100.9080.2080.2059.5059.5038.8038.8018.1018.10Harga Sasaran MedianQ3 '20Q3 '20Q4 '20Q4 '20Q1 '21Q1 '21Q2 '21Q2 '21Q3 '21Q3 '21Q4 '21Q4 '21Q1 '22Q1 '22Q2 '22Q2 '22Q3 '22Q3 '22Q4 '22Q4 '22Q1 '23Q1 '23Q2 '23Q2 '23Q3 '23Q3 '23Q4 '23Q4 '23Q1 '24Q1 '24Q2 '24Q2 '24Q3 '24Q3 '24Q4 '24Q4 '24Q1 '25Q1 '25Q2 '25Q2 '25
Julat 52 Minggu
16.97 (-20%) — 35.84 (66%)
Julat Harga Sasaran
35.00 (63%) — 40.00 (86%)
Tinggi 40.00 (Scotiabank, 86.31%) Beli
Median 37.00 (72.33%)
Rendah 35.00 (Lake Street, 63.02%) Beli
Purata 37.33 (73.87%)
Jumlah 3 Beli
Harga Purata @ Panggilan 16.42
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Scotiabank 21 May 2025 40.00 (86.31%) Beli 16.02
Canaccord Genuity 06 May 2025 37.00 (72.33%) Beli 16.62
Lake Street 06 May 2025 35.00 (63.02%) Beli 16.62

Tiada data dalam julat masa ini.

Tarikh Jenis Butiran
21 May 2025 Pengumuman Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference
09 May 2025 Pengumuman Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result
07 May 2025 Pengumuman Castle Biosciences Celebrates Skin Cancer Awareness Month
05 May 2025 Pengumuman Castle Biosciences Reports First Quarter 2025 Results
05 May 2025 Pengumuman Castle Biosciences to Acquire Previse
02 May 2025 Pengumuman New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer
30 Apr 2025 Pengumuman New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity
28 Apr 2025 Pengumuman DecisionDx®-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma
25 Apr 2025 Pengumuman New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis
14 Apr 2025 Pengumuman Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025
08 Apr 2025 Pengumuman Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships
07 Apr 2025 Pengumuman Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year
03 Apr 2025 Pengumuman Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences’ DecisionDx®-Melanoma Test
01 Apr 2025 Pengumuman Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma
28 Mar 2025 Pengumuman Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups
07 Mar 2025 Pengumuman New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio
Papar semua
18.5218.5217.4817.4816.4416.4415.4015.4014.3614.36May 14May 14May 15May 15May 16May 16May 19May 19May 20May 20May 21May 21May 22May 22May 23May 23

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
1.0001.0000.5000.5000.0000.000-0.500-0.500-1.000-1.000MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda